Young Potenza’s Promise Attracts Astellas As Potential Buyer
This article was originally published in PharmAsia News
Executive Summary
Astellas has secured an option to acquire the U.S. biotech Potenza as part of a new R&D alliance focusing on immuno-oncology candidates.